Literature DB >> 6257825

Serological and immunological relations between the 146S and 12S particles of foot-and-mouth disease virus.

B Cartwright, W G Chapman, F Brown.   

Abstract

Intact 146S particles of the seven serotypes of foot-and-mouth disease virus (FMDV) produce type-specific precipitating, complement-fixing and neutralizing antibodies in cattle and guinea-pigs. However, the 12S structural subunit, produced from the virus particle by mild acid treatment (pH 6) or by heating at 56 degrees C, although stimulating the production of precipitating and complement-fixing antibodies, produces only low levels of neutralizing antibody. Nevertheless, 12S antibody in guinea-pigs primed with a vaccine prepared from 146S particles. Moreover, heterotypic 12S and 146S particles also boosted the neutralizing antibody response to the first virus. These results point to an antigenic similarity between the 146S particles of each type and to a close antigenic relationship between the 146S and 12S particles.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6257825     DOI: 10.1099/0022-1317-50-2-369

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

Review 1.  An overview on ELISA techniques for FMD.

Authors:  Li-na Ma; Jie Zhang; Hao-tai Chen; Jian-hua Zhou; Yao-zhong Ding; Yong-sheng Liu
Journal:  Virol J       Date:  2011-09-04       Impact factor: 4.099

2.  An enzyme-linked immunosorbent assay (ELISA) for the primary diagnosis of foot-and-mouth disease. Characterization and comparison with complement fixation.

Authors:  P Have; J C Lei; K Schjerning-Thiesen
Journal:  Acta Vet Scand       Date:  1984       Impact factor: 1.695

3.  Comparison of the major antigenic determinants of different serotypes of foot-and-mouth disease virus.

Authors:  A Cheung; J DeLamarter; S Weiss; H Küpper
Journal:  J Virol       Date:  1983-11       Impact factor: 5.103

4.  Foot-and-mouth disease virus assembly: processing of recombinant capsid precursor by exogenous protease induces self-assembly of pentamers in vitro in a myristoylation-dependent manner.

Authors:  Stewart Goodwin; Tobias J Tuthill; Armando Arias; Richard A Killington; David J Rowlands
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

5.  Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids.

Authors:  S Curry; C C Abrams; E Fry; J C Crowther; G J Belsham; D I Stuart; A M King
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

6.  Structures of foot and mouth disease virus pentamers: Insight into capsid dissociation and unexpected pentamer reassociation.

Authors:  Nayab Malik; Abhay Kotecha; Sarah Gold; Amin Asfor; Jingshan Ren; Juha T Huiskonen; Tobias J Tuthill; Elizabeth E Fry; David I Stuart
Journal:  PLoS Pathog       Date:  2017-09-22       Impact factor: 6.823

7.  Production of a Foot-and-Mouth Disease Vaccine Antigen Using Suspension-Adapted BHK-21 Cells in a Bioreactor.

Authors:  Soonyong Park; Ji Yul Kim; Kyoung-Hwa Ryu; Ah-Young Kim; Jaemun Kim; Young-Joon Ko; Eun Gyo Lee
Journal:  Vaccines (Basel)       Date:  2021-05-13

8.  Novel Capsid-Specific Single-Domain Antibodies with Broad Foot-and-Mouth Disease Strain Recognition Reveal Differences in Antigenicity of Virions, Empty Capsids, and Virus-Like Particles.

Authors:  Haozhou Li; Aldo Dekker; Shiqi Sun; Alison Burman; Jeroen Kortekaas; Michiel M Harmsen
Journal:  Vaccines (Basel)       Date:  2021-06-08

9.  An Engineered Maturation Cleavage Provides a Recombinant Mimic of Foot-and-Mouth Disease Virus Capsid Assembly-Disassembly.

Authors:  Joseph Newman; David J Rowlands; Tobias J Tuthill
Journal:  Life (Basel)       Date:  2021-05-29

10.  Quantitative Detection of the Foot-And-Mouth Disease Virus Serotype O 146S Antigen for Vaccine Production Using a Double-Antibody Sandwich ELISA and Nonlinear Standard Curves.

Authors:  Xia Feng; Jun-Wu Ma; Shi-Qi Sun; Hui-Chen Guo; Ya-Min Yang; Ye Jin; Guang-Qing Zhou; Ji-Jun He; Jian-Hong Guo; Shu-yun Qi; Mi Lin; Hu Cai; Xiang-Tao Liu
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.